FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2897424463> ?p ?o ?g. }

• W2897424463 endingPage "e182140" @default.
• W2897424463 startingPage "e182140" @default.
• W2897424463 abstract "Detection of disease-associated variants in the BRCA1 and BRCA2 (BRCA1/2) genes allows for cancer prevention and early diagnosis in high-risk individuals.To identify pathogenic and likely pathogenic (P/LP) BRCA1/2 variants in an unselected research cohort, and to characterize the features associated with P/LP variants.This is a cross-sectional study of adult volunteers (n = 50 726) who underwent exome sequencing at a single health care system (Geisinger Health System, Danville, Pennsylvania) from January 1, 2014, to March 1, 2016. Participants are part of the DiscovEHR cohort and were identified through the Geisinger MyCode Community Health Initiative. They consented to a research protocol that included sequencing and return of actionable test results. Clinical data from electronic health records and clinical visits were correlated with variants. Comparisons were made between those with (cases) and those without (controls) P/LP variants in BRCA1/2.Prevalence of P/LP BRCA1/2 variants in cohort, proportion of variant carriers not previously ascertained through clinical testing, and personal and family history of relevant cancers among BRCA1/2 variant carriers and noncarriers.Of the 50 726 health system patients who underwent exome sequencing, 50 459 (99.5%) had no expected pathogenic BRCA1/2 variants and 267 (0.5%) were BRCA1/2 carriers. Of the 267 cases (148 [55.4%] were women and 119 [44.6%] were men with a mean [range] age of 58.9 [23-90] years), 183 (68.5%) received clinically confirmed results in their electronic health record. Among the 267 participants with P/LP BRCA1/2 variants, 219 (82.0%) had no prior clinical testing, 95 (35.6%) had BRCA1 variants, and 172 (64.4%) had BRCA2 variants. Syndromic cancer diagnoses were present in 11 (47.8%) of the 23 deceased BRCA1/2 carriers and in 56 (20.9%) of all 267 BRCA1/2 carriers. Among women, 31 (20.9%) of 148 variant carriers had a personal history of breast cancer, compared with 1554 (5.2%) of 29 880 noncarriers (odds ratio [OR], 5.95; 95% CI, 3.88-9.13; P < .001). Ovarian cancer history was present in 15 (10.1%) of 148 variant carriers and in 195 (0.6%) of 29 880 variant noncarriers (OR, 18.30; 95% CI, 10.48-31.4; P < .001). Among 89 BRCA1/2 carriers without prior testing but with comprehensive personal and family history data, 44 (49.4%) did not meet published guidelines for clinical testing.This study found that compared with previous clinical care, exome sequencing-based screening identified 5 times as many individuals with P/LP BRCA1/2 variants. These findings suggest that genomic screening may identify BRCA1/2-associated cancer risk that might otherwise remain undetected within health care systems and may provide opportunities to reduce morbidity and mortality in patients." @default.
• W2897424463 created "2018-10-26" @default.
• W2897424463 creator A5002394633 @default.
• W2897424463 creator A5003719393 @default.
• W2897424463 creator A5004853015 @default.
• W2897424463 creator A5008633222 @default.
• W2897424463 creator A5009326615 @default.
• W2897424463 creator A5010898091 @default.
• W2897424463 creator A5011394180 @default.
• W2897424463 creator A5013798428 @default.
• W2897424463 creator A5018275663 @default.
• W2897424463 creator A5020019979 @default.
• W2897424463 creator A5020788097 @default.
• W2897424463 creator A5023074057 @default.
• W2897424463 creator A5023818363 @default.
• W2897424463 creator A5025311418 @default.
• W2897424463 creator A5027472502 @default.
• W2897424463 creator A5028005682 @default.
• W2897424463 creator A5028966241 @default.
• W2897424463 creator A5032050931 @default.
• W2897424463 creator A5032100711 @default.
• W2897424463 creator A5032814784 @default.
• W2897424463 creator A5039407032 @default.
• W2897424463 creator A5039843757 @default.
• W2897424463 creator A5041306543 @default.
• W2897424463 creator A5050850261 @default.
• W2897424463 creator A5051486097 @default.
• W2897424463 creator A5052909633 @default.
• W2897424463 creator A5053857264 @default.
• W2897424463 creator A5053881786 @default.
• W2897424463 creator A5056125364 @default.
• W2897424463 creator A5056355361 @default.
• W2897424463 creator A5057175194 @default.
• W2897424463 creator A5057563096 @default.
• W2897424463 creator A5058487870 @default.
• W2897424463 creator A5061974826 @default.
• W2897424463 creator A5063181531 @default.
• W2897424463 creator A5066636070 @default.
• W2897424463 creator A5074651593 @default.
• W2897424463 creator A5077135987 @default.
• W2897424463 creator A5080513272 @default.
• W2897424463 creator A5080516152 @default.
• W2897424463 creator A5081769614 @default.
• W2897424463 creator A5087349100 @default.
• W2897424463 creator A5088758683 @default.
• W2897424463 creator A5089464311 @default.
• W2897424463 date "2018-09-21" @default.
• W2897424463 modified "2023-10-16" @default.
• W2897424463 title "Exome Sequencing–Based Screening for <i>BRCA1/2</i> Expected Pathogenic Variants Among Adult Biobank Participants" @default.
• W2897424463 cites W1129192333 @default.
• W2897424463 cites W1964598131 @default.
• W2897424463 cites W1971130848 @default.
• W2897424463 cites W1997863242 @default.
• W2897424463 cites W2018130645 @default.
• W2897424463 cites W2030093162 @default.
• W2897424463 cites W2051978340 @default.
• W2897424463 cites W2065398377 @default.
• W2897424463 cites W2084988326 @default.
• W2897424463 cites W2096841153 @default.
• W2897424463 cites W2100787726 @default.
• W2897424463 cites W2101192995 @default.
• W2897424463 cites W2109465247 @default.
• W2897424463 cites W2119818111 @default.
• W2897424463 cites W2126170418 @default.
• W2897424463 cites W2130844237 @default.
• W2897424463 cites W2137382955 @default.
• W2897424463 cites W2142181526 @default.
• W2897424463 cites W2160818861 @default.
• W2897424463 cites W2162096542 @default.
• W2897424463 cites W2174602966 @default.
• W2897424463 cites W2271788388 @default.
• W2897424463 cites W2320983896 @default.
• W2897424463 cites W2443172870 @default.
• W2897424463 cites W2507763620 @default.
• W2897424463 cites W2516720184 @default.
• W2897424463 cites W2562408240 @default.
• W2897424463 cites W2567297878 @default.
• W2897424463 cites W2579423964 @default.
• W2897424463 cites W2627871710 @default.
• W2897424463 cites W2745994405 @default.
• W2897424463 cites W2765196994 @default.
• W2897424463 cites W2801903570 @default.
• W2897424463 cites W2885924260 @default.
• W2897424463 cites W2951672808 @default.
• W2897424463 cites W4213127756 @default.
• W2897424463 cites W4247623075 @default.
• W2897424463 cites W4252946660 @default.
• W2897424463 cites W4297625640 @default.
• W2897424463 doi "https://doi.org/10.1001/jamanetworkopen.2018.2140" @default.
• W2897424463 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6324494" @default.
• W2897424463 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30646163" @default.
• W2897424463 hasPublicationYear "2018" @default.
• W2897424463 type Work @default.
• W2897424463 sameAs 2897424463 @default.
• W2897424463 citedByCount "146" @default.
• W2897424463 countsByYear W28974244632019 @default.
• W2897424463 countsByYear W28974244632020 @default.
• W2897424463 countsByYear W28974244632021 @default.

• next